MoonLake Immunotherapeutics (MLTX) Liabilities and Shareholders Equity (2020 - 2026)

MoonLake Immunotherapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $400.4 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 21.69% year-over-year to $400.4 million; the TTM figure through Mar 2026 stood at $1.7 billion (down 17.2% YoY), while the FY2025 annual figure was $424.4 million, down 11.19% from the prior year.
• Liabilities and Shareholders Equity was $400.4 million for Q1 2026 at MoonLake Immunotherapeutics, down from $424.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $564.1 million in Q1 2024 to a low of $66.8 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $377.1 million across 5 years, with a median of $460.1 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity tumbled 71.11% in 2023, then surged 744.53% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $76.8 million in 2022, then jumped by 585.21% to $526.5 million in 2023, then slipped by 9.23% to $477.9 million in 2024, then retreated by 11.19% to $424.4 million in 2025, then retreated by 5.67% to $400.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $400.4 million (Q1 2026), $424.4 million (Q4 2025), and $414.3 million (Q3 2025), per Business Quant data.